睿智医药(300149) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥389,706,314.16, representing a 39.81% increase compared to ¥278,744,900.86 in the same period last year[8]. - Net profit attributable to shareholders was ¥1,631,770.54, a significant turnaround from a loss of ¥14,153,944.58, marking an increase of 111.53%[8]. - The net cash flow from operating activities reached ¥65,025,423.75, up 277.45% from ¥17,227,621.05 in the previous year[8]. - Basic and diluted earnings per share improved to ¥0.003 from a loss of ¥0.028, reflecting a 110.71% increase[8]. - The company achieved operating revenue of RMB 389.71 million in Q1 2021, representing a year-on-year increase of 39.81%[24]. - The net profit attributable to ordinary shareholders was RMB 1.63 million, marking a turnaround from a loss in the same period last year[24]. - The company reported a gross profit margin of approximately -1.1% for Q1 2021, compared to -5.9% in the previous year[43]. - The company experienced a total comprehensive loss of CNY 1.98 million in Q1 2021, compared to a loss of CNY 11.57 million in the same period last year[44]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,771,657,614.89, a 15.77% increase from ¥4,121,581,017.24 at the end of the previous year[8]. - The total liabilities increased to CNY 2,341,695,235.37 from CNY 1,669,193,302.07, reflecting a rise of approximately 40.2%[36]. - The company's current assets totaled CNY 942,292,294.06, compared to CNY 919,879,207.40 at the end of 2020, indicating a slight increase of about 2.5%[34]. - The total liabilities as of the end of Q1 2021 were CNY 955.25 million, compared to CNY 928.48 million at the end of the previous year[43]. - The company reported a decrease in accounts payable to CNY 99,485,992.11 from CNY 77,236,033.59, an increase of about 28.8%[36]. Shareholder Information - The total number of shareholders at the end of the reporting period was 16,002[12]. - The largest shareholder, Yunnan Baben Health Industry Co., Ltd., held 16.05% of the shares, amounting to 80,199,000 shares[12]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13]. - The company repurchased 1,450,000 shares, accounting for 0.29% of the total share capital, with a total expenditure of RMB 20.44 million[27]. Research and Development - Research and development expenses increased by 181.12% to RMB 24.81 million, reflecting the company's commitment to enhancing R&D investment[21]. - The pharmaceutical R&D and production outsourcing business generated revenue of RMB 305.95 million, up 37.31% year-on-year[24]. - Research and development expenses increased to CNY 24.81 million in Q1 2021, up from CNY 8.82 million in the same period last year, reflecting a focus on innovation[43]. Cash Flow - Operating cash inflow from sales increased to ¥395,537,010.87, up from ¥256,847,435.91, representing a growth of 54.2%[49]. - Net cash flow from financing activities improved to ¥63,937,725.44, up from ¥37,742,319.47, reflecting an increase of 69.5%[51]. - The company reported a net increase in cash and cash equivalents of ¥39,241,732.40, compared to a decrease of ¥76,569,086.18 in the previous period[51]. - Cash outflow from investment activities totaled ¥192,581,927.93, down from ¥323,207,835.22, indicating a reduction of 40.5%[50]. Future Outlook - The company plans to continue its market expansion efforts and maintain focus on R&D to drive future growth[24].